RS52094B - Swelling erodible matrix system with controlled active substance release - Google Patents

Swelling erodible matrix system with controlled active substance release

Info

Publication number
RS52094B
RS52094B YU64603A YUP64603A RS52094B RS 52094 B RS52094 B RS 52094B YU 64603 A YU64603 A YU 64603A YU P64603 A YUP64603 A YU P64603A RS 52094 B RS52094 B RS 52094B
Authority
RS
Serbia
Prior art keywords
active substance
swelling
erodible matrix
matrix system
substance release
Prior art date
Application number
YU64603A
Other languages
Serbian (sr)
Inventor
Aleksandra PETROVIĆ
Tatjana KORAĆ
Radmila POPOVIĆ
Jadranka DELETIĆ
Dragica POPADIĆ
Rada FILIPOVIĆ
Dijamanda DŽELETOVIĆ
Original Assignee
Galenika A.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galenika A.D. filed Critical Galenika A.D.
Priority to YU64603A priority Critical patent/RS52094B/en
Publication of YU64603A publication Critical patent/YU64603A/en
Publication of RS52094B publication Critical patent/RS52094B/en

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

Farmaceutski proizvod, u obliku tableta i/ili filmom obloženih tableta, koji predstavlja bubreći erodibilni matriks sa kontrolisanim i kontinualnim oslobađanjem aktivne supstance u toku 12 sati, naznačen time, što sadrži u visokoj koncentraciji (55-89% w/w) aktivnu supstancu različite rastvorljivosti, bubreći erodibilni polimer (5-25%) iz grupe HPMC, tip 2208 USP, i/ili kanal formirajuće sredstvo (1-28%) iz grupe punioca lako rastvornih u vodi, vezivno sredstvo do 3,5%. kao i male količine drugih, farmaceutski prihvatljivih, pomoćnih supstanci i/ili film formirajuću oblogu (0,5-14% u odnosu na suvu masu tablete).Prijava sadrži još 1 nezavisan i 10 zavisnih patentnih zahteva.A pharmaceutical product, in tablet form and / or film-coated tablet form, which is a swollen erodible matrix with controlled and continuous release of the active substance for 12 hours, containing at high concentration (55-89% w / w) a different active ingredient solubility, swellable erodible polymer (5-25%) of HPMC group, type 2208 USP, and / or channel forming agent (1-28%) of filler group readily soluble in water, binder up to 3.5%. as well as small amounts of other pharmaceutically acceptable excipients and / or film-forming coating (0.5-14% by weight of tablet). The application contains 1 more independent and 10 dependent claims.

YU64603A 2003-08-12 2003-08-12 Swelling erodible matrix system with controlled active substance release RS52094B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
YU64603A RS52094B (en) 2003-08-12 2003-08-12 Swelling erodible matrix system with controlled active substance release

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
YU64603A RS52094B (en) 2003-08-12 2003-08-12 Swelling erodible matrix system with controlled active substance release

Publications (2)

Publication Number Publication Date
YU64603A YU64603A (en) 2006-05-25
RS52094B true RS52094B (en) 2012-06-30

Family

ID=37616573

Family Applications (1)

Application Number Title Priority Date Filing Date
YU64603A RS52094B (en) 2003-08-12 2003-08-12 Swelling erodible matrix system with controlled active substance release

Country Status (1)

Country Link
RS (1) RS52094B (en)

Also Published As

Publication number Publication date
YU64603A (en) 2006-05-25

Similar Documents

Publication Publication Date Title
RS51330B (en) Stable pharmaceutical formulations of montelukast sodium
NO20070719L (en) Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, process for its preparation and use thereof
MX2008000099A (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof.
NO20071853L (en) Pharmaceutical composition containing a solid dispersion with a polymer matrix containing a uniform polydextrose phase and a uniform phase of a polymer different from polydextrose.
RS51934B (en) Modified-release tablet of bupropion hydrochloride
DK0923934T3 (en) Modified release matrix formulation of cefaclor and cephalexin
BR0211317A (en) System for controlled drug release through gastric retention
NO20092998L (en) Liquid formulations, which form dermal films, for the release of drugs to the skin
AU5251896A (en) Controlled release formulation for water soluble drugs in which a passageway is formed in situ
ATE288256T1 (en) DERMAL COMPOSITIONS
BRPI9915142B8 (en) new pharmaceutical material in the form of pearls with controlled release, respective method of production and formulation of multiple inities comprising the same
TW200503775A (en) Pharmaceutical composition and method for treating
NO20083027L (en) Controlled release solid formulation
MX2008013040A (en) Benzimidazole 5-sulfonamide derivatives as cannabinoid 1 (cb1) receptor ligands.
NO20056241L (en) Nanoparticles of polyoxyethylenated derivatives
KR960010007A (en) Gephyron Dose Type
TN2009000197A1 (en) Sustained - release composition and method for producing the same
AR061166A1 (en) PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF PHENYLPHERINE
RU2008142129A (en) ASYMMETRIC MEMBRANES FOR DRUG DELIVERY DEVICES
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
PE20000169A1 (en) TROVAFLOXACINE MESYLATE TABLET
BR112012012248A2 (en) film coating agent for a solid formulation, and solid formulation
HRP20010342B1 (en) Pharmaceutical composition for modified release insulin sensitiser
MX2008010879A (en) Fluvastatin sodium pharmaceutical compositions.
WO2005107716A1 (en) Controlled release paroxetine-containing tablets based on a core and a coating